局部晚期口咽癌的治疗现状及研究进展综述
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i2.13425
Abstract
口咽癌作为头颈部常见的恶性肿瘤之一,近年来其发病呈现出一定的上升趋势。口咽癌早期缺乏典型临床症状,且临床90%以上的口咽癌为鳞癌,恶性程度较高,晚期易向周围结构及深层肌内侵犯。随着临床医疗技术的不断发展,口咽癌的治疗发生了一系列变化,手术适应证的扩大提高了局部晚期口咽患者的生存率和生活质量。此外,伴随临床对恶性肿瘤治疗开始重视器官和功能保留,局部晚期口咽癌的治疗需要平衡根治肿瘤和生活质量。故本文通过综述局部晚期口咽癌的治疗现状,同时探讨当前的研究热点与未来发展方向,以期为临床治疗决策提供参考依据,推动该领域研究迈向新高度。
Keywords
局部晚期口咽癌;口咽癌;治疗;生存率
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 李建成,陈传俊,薛浩伟,等.2015—2020年安徽皖北地区口咽癌发病与死亡分析[J].中华全科学,2022,20(8):1411-1414,1422.
[2] Singhavi R H,Chaturvedi P,Nair D.The Human Papillomav irus Enigma:A Narrative Review of Global Variations in Orophar yngeal Cancer Epidemiology and Prognosis.[J].Indian journal of public health,2024,68(2):268-275.
[3] K A C,D N F,C C A.The Evolving Epidemiology of Oral Cavi ty and Oropharyngeal Cancers.[J].Cancer research,2022,82(16):2821-2823.
[4] Sampieri C,Cioccoloni E,Costantino A,et al.Neoadjuvant chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis.[J].Head & neck,2024,47(1):175-188.
[5] Aristizabal P L A,Barbosa G C D,Roger A S,et al.Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Larynx: A Scoping Review of Treatment Guidelines Worldwide[J].Cancers,2023,15(17):4405.
[6] Kamal M ,Peeler R C ,Yepes P , et al.Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma[J].Advances in Radiation Oncology,2020,5(1):111-119.
[7] 阮敏,韩楠男,安常明,等.口咽癌外科治疗专家共识[J].口腔疾病防治,2024,32(11):821-833.
[8] Baude J,Guigou C,Thibouw D,et al.Definitive radio(chemo) therapy versus upfront surgery in the treatment of HPV-relat ed localized or locally advanced oropharyngeal squamous cell carcinoma[J].PloS one,2024,19(7):e0307658.
[9] Park DA, Lee MJ, Kim SH, Lee SH. Comparative safety and effectiveness of transoral robotic surgery versus open surge ry for oropharyngeal cancer:A systematic review and metaanalysis[J].Eur J Surg Oncol.2020;46(4 Pt A):644-649.
[10] M D D ,X L Y ,O F O , et al.Racial disparities in surgical treatment of oropharyngeal cancer:A Surveillance, Epidemiol ogy,and End Results review.[J].Head & neck,2023,45(9):2313-2322.
[11] 黄志刚,文卫平,毛薇,等.头颈肿瘤的综合治疗策略[J].临床耳鼻咽喉头颈外科杂志,2023,37(9):673-690.
[12] Youssef I,Yoon J,Mohamed N,et al, Toxicity profiles and survival outcomes among patients with nonmetastatic oropharyngealcarcinoma treated with intensitymodulated pro ton therapy vs intensity-modulated radiation therapy[J/OL],JAMA Netw Open,2022,5(11):e2241538[2025-03-26].https://pub med,ncbi.nlm.nih,gov/36367724/.
[13] Razavian B N ,Shenker F R ,Smith S , et al.Toxicity and Oncologic Outcomes of Proton Radiotherapy for Oropharyngeal Cancer:A Systematic Review and Meta-Analysis.[J].Cureus,2025,17(2):e78849.
[14] Puneet N ,U S ,Deep P , et al.Comparison of concurrent chemoradiation with daily gefitinib versus daily erlotinib in locally advanced oropharyngeal cancers[J].Clinical Cancer Investigation Journal,2021,10(4):203-208.
[15] H.G,T.Z,M.L,et al.Radical Surgery vs.Definitive Concu rrent Chemoradiotherapy for Locally Advanced Hypopharyngeal Cancer[J].International Journal of Radiation Oncology, Biology, Physics,2021,111(3S):e363.
[16] 张冬.IMRT放疗联合TP化疗治疗局部晚期口咽癌患者的疗效分析[J].实用中西医结合临床,2020,20(1):49-50.
[17] Thorstad W,Jackson R,Oppelt P,et al.Long-Term Effica cy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+OPSCC):A Non-Randomized,Multi-Arm Phase 2 Trial[J]. International Journal of Radiation Oncology, Biology, Physics,2024,118(5):e10.
[18] Sampieri C,Cioccoloni E,Costantino A,et al.Neoadjuva nt chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis.[J].Head & neck,2024,47(1):175-188.
[19] 刘乾,张杰.局部晚期口腔及口咽鳞癌新辅助治疗与手术优先治疗对照分析[J].现代口腔医学杂志,2024,38(3):207-211.
[20] Liu Y X,Guan S J H ,Zhang W ,et al.Efficacy of PD-1 inhibitor with neoadjuvant chemotherapy in hypopharyngeal and oropharyngeal cancer[J].Frontiers in Oncology,2024,14:1450830.
[21] Sadeghi N,Subramaniam T,Richardson K,et al.Neoadjuv ant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Cancer.[J].JAMA Otolar yngol Head Neck Surg.2025,151(2):128-134.
[22] Baran E,Lee M,Aviv S,et al.Oropharyngeal Cancer Stag ing Health Record Extraction Using Artificial Intelligence [J].JAMA Otolaryngol Head Neck Surg. 2024,150(12):1051-1057.
[23] Guo M ,Jian Y ,Chen J , et al.Prospective feasibilities and strategies of MOFs on the treatment of oropharyngeal carcinoma[J].Materials Today Chemistry,2025,45:102627.
[2] Singhavi R H,Chaturvedi P,Nair D.The Human Papillomav irus Enigma:A Narrative Review of Global Variations in Orophar yngeal Cancer Epidemiology and Prognosis.[J].Indian journal of public health,2024,68(2):268-275.
[3] K A C,D N F,C C A.The Evolving Epidemiology of Oral Cavi ty and Oropharyngeal Cancers.[J].Cancer research,2022,82(16):2821-2823.
[4] Sampieri C,Cioccoloni E,Costantino A,et al.Neoadjuvant chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis.[J].Head & neck,2024,47(1):175-188.
[5] Aristizabal P L A,Barbosa G C D,Roger A S,et al.Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Larynx: A Scoping Review of Treatment Guidelines Worldwide[J].Cancers,2023,15(17):4405.
[6] Kamal M ,Peeler R C ,Yepes P , et al.Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma[J].Advances in Radiation Oncology,2020,5(1):111-119.
[7] 阮敏,韩楠男,安常明,等.口咽癌外科治疗专家共识[J].口腔疾病防治,2024,32(11):821-833.
[8] Baude J,Guigou C,Thibouw D,et al.Definitive radio(chemo) therapy versus upfront surgery in the treatment of HPV-relat ed localized or locally advanced oropharyngeal squamous cell carcinoma[J].PloS one,2024,19(7):e0307658.
[9] Park DA, Lee MJ, Kim SH, Lee SH. Comparative safety and effectiveness of transoral robotic surgery versus open surge ry for oropharyngeal cancer:A systematic review and metaanalysis[J].Eur J Surg Oncol.2020;46(4 Pt A):644-649.
[10] M D D ,X L Y ,O F O , et al.Racial disparities in surgical treatment of oropharyngeal cancer:A Surveillance, Epidemiol ogy,and End Results review.[J].Head & neck,2023,45(9):2313-2322.
[11] 黄志刚,文卫平,毛薇,等.头颈肿瘤的综合治疗策略[J].临床耳鼻咽喉头颈外科杂志,2023,37(9):673-690.
[12] Youssef I,Yoon J,Mohamed N,et al, Toxicity profiles and survival outcomes among patients with nonmetastatic oropharyngealcarcinoma treated with intensitymodulated pro ton therapy vs intensity-modulated radiation therapy[J/OL],JAMA Netw Open,2022,5(11):e2241538[2025-03-26].https://pub med,ncbi.nlm.nih,gov/36367724/.
[13] Razavian B N ,Shenker F R ,Smith S , et al.Toxicity and Oncologic Outcomes of Proton Radiotherapy for Oropharyngeal Cancer:A Systematic Review and Meta-Analysis.[J].Cureus,2025,17(2):e78849.
[14] Puneet N ,U S ,Deep P , et al.Comparison of concurrent chemoradiation with daily gefitinib versus daily erlotinib in locally advanced oropharyngeal cancers[J].Clinical Cancer Investigation Journal,2021,10(4):203-208.
[15] H.G,T.Z,M.L,et al.Radical Surgery vs.Definitive Concu rrent Chemoradiotherapy for Locally Advanced Hypopharyngeal Cancer[J].International Journal of Radiation Oncology, Biology, Physics,2021,111(3S):e363.
[16] 张冬.IMRT放疗联合TP化疗治疗局部晚期口咽癌患者的疗效分析[J].实用中西医结合临床,2020,20(1):49-50.
[17] Thorstad W,Jackson R,Oppelt P,et al.Long-Term Effica cy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+OPSCC):A Non-Randomized,Multi-Arm Phase 2 Trial[J]. International Journal of Radiation Oncology, Biology, Physics,2024,118(5):e10.
[18] Sampieri C,Cioccoloni E,Costantino A,et al.Neoadjuva nt chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis.[J].Head & neck,2024,47(1):175-188.
[19] 刘乾,张杰.局部晚期口腔及口咽鳞癌新辅助治疗与手术优先治疗对照分析[J].现代口腔医学杂志,2024,38(3):207-211.
[20] Liu Y X,Guan S J H ,Zhang W ,et al.Efficacy of PD-1 inhibitor with neoadjuvant chemotherapy in hypopharyngeal and oropharyngeal cancer[J].Frontiers in Oncology,2024,14:1450830.
[21] Sadeghi N,Subramaniam T,Richardson K,et al.Neoadjuv ant Chemotherapy and Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Cancer.[J].JAMA Otolar yngol Head Neck Surg.2025,151(2):128-134.
[22] Baran E,Lee M,Aviv S,et al.Oropharyngeal Cancer Stag ing Health Record Extraction Using Artificial Intelligence [J].JAMA Otolaryngol Head Neck Surg. 2024,150(12):1051-1057.
[23] Guo M ,Jian Y ,Chen J , et al.Prospective feasibilities and strategies of MOFs on the treatment of oropharyngeal carcinoma[J].Materials Today Chemistry,2025,45:102627.
Copyright © 2025 韦晓丹, 徐志坚

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License